This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2f9k

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2f9k.gif|left|200px]]
+
{{Seed}}
 +
[[Image:2f9k.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2f9k| PDB=2f9k | SCENE= }}
{{STRUCTURE_2f9k| PDB=2f9k | SCENE= }}
-
'''Crystal structure of human FPPS in complex with Zoledronate and Zn2+'''
+
===Crystal structure of human FPPS in complex with Zoledronate and Zn2+===
-
==Overview==
+
<!--
-
To understand the structural basis for bisphosphonate therapy of bone diseases, we solved the crystal structures of human farnesyl pyrophosphate synthase (FPPS) in its unliganded state, in complex with the nitrogen-containing bisphosphonate (N-BP) drugs zoledronate, pamidronate, alendronate, and ibandronate, and in the ternary complex with zoledronate and the substrate isopentenyl pyrophosphate (IPP). By revealing three structural snapshots of the enzyme catalytic cycle, each associated with a distinct conformational state, and details about the interactions with N-BPs, these structures provide a novel understanding of the mechanism of FPPS catalysis and inhibition. In particular, the accumulating substrate, IPP, was found to bind to and stabilize the FPPS-N-BP complexes rather than to compete with and displace the N-BP inhibitor. Stabilization of the FPPS-N-BP complex through IPP binding is supported by differential scanning calorimetry analyses of a set of representative N-BPs. Among other factors such as high binding affinity for bone mineral, this particular mode of FPPS inhibition contributes to the exceptional in vivo efficacy of N-BP drugs. Moreover, our data form the basis for structure-guided design of optimized N-BPs with improved pharmacological properties.
+
The line below this paragraph, {{ABSTRACT_PUBMED_16892359}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 16892359 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_16892359}}
==About this Structure==
==About this Structure==
Line 38: Line 42:
[[Category: Isoprene biosynthesis]]
[[Category: Isoprene biosynthesis]]
[[Category: Mevalonate pathway]]
[[Category: Mevalonate pathway]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 03:37:53 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Jul 27 22:39:04 2008''

Revision as of 19:39, 27 July 2008

Image:2f9k.png

Template:STRUCTURE 2f9k

Crystal structure of human FPPS in complex with Zoledronate and Zn2+

Template:ABSTRACT PUBMED 16892359

About this Structure

2F9K is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs., Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W, ChemMedChem. 2006 Feb;1(2):267-73. PMID:16892359

Page seeded by OCA on Sun Jul 27 22:39:04 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2f9k"
Personal tools